elesclomol

Separately, Synta Pharmaceuticals Corp. said Monday that a cancer-drug venture involving Glaxo and elesclomol would end within 90 days, putting the treatment further into question after a late-stage trial was stopped earlier this year amid mortality concerns.

Glaxo Seals 2009

Synta is expected to present data from its Phase 3 elesclomol study Symmetry during mid-2009, according to Susquehanna Financial Group.

Options Traders Circle Drug Firms 2009

This was the case in the elesclomol and AS404 studies, which showed an impressive numeric difference in OS which was not statistically significant.

unknown title 2011

The company later said elesclomol did not meet its goal in the trial.

D Mag - News 2010

The company said patients with high LDH have lower oxygen levels, which changes the metabolism of cancer cells and reduces the effectiveness of elesclomol.

D Mag - News 2010

Synta Pharmaceuticals Corp. said Tuesday it will restart development of its skin cancer drug candidate elesclomol.

D Mag - News 2010

In patients with normal LDH levels, study data show a combination of elesclomol and the chemotherapy drug paclitaxel was significantly more effective than paclitaxel alone, Synta said.

D Mag - News 2010

Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual

American Chronicle 2010

Research on elesclomol in skin cancer was stopped in February 2009 because of unexpected numbers of deaths among test subjects who took the drug.

D Mag - News 2010

Earlier research shows that elesclomol helped extend the lives of patients with normal LDH levels but did not work as well on patients with high LDH levels.

D Mag - News 2010